Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Sarcoma 40Neoplasm Metastasis 7Leiomyosarcoma 7Liposarcoma 6Hemangiosarcoma 6Neurofibrosarcoma 5Sarcoma, Synovial 4Osteosarcoma 4Histiocytoma, Malignant Fibrous 4Glioblastoma 4Dermatofibrosarcoma 4Chondrosarcoma, Extraskeletal Myxoid 4Sarcoma, Alveolar Soft Part 3Neoplasms 3Gliosarcoma 3Gastrointestinal Stromal Tumors 3Fibrosarcoma 3Breast Neoplasms 3Brain Neoplasms 3Solitary Fibrous Tumors 2Sarcoma, Clear Cell 2Rhabdomyosarcoma 2Recurrence 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Nerve Sheath Neoplasms 2Histiocytoma, Angiomatoid Fibrous 2Hemangioendothelioma, Epithelioid 2Granuloma, Plasma Cell 2Carcinoma, Renal Cell 2

Interventions

Cyclophosphamide 23Temozolomide 14Filgrastim 13Irinotecan 12Melphalan 11Etoposide 10Carboplatin 9Vincristine 8Peripheral Blood Stem Cell Transplantation 8Granulocyte Colony-Stimulating Factor 8X-Rays 7Topotecan 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Busulfan 7fludarabine 6Thiotepa 6Phantoms, Imaging 6fludarabine phosphate 5Radiotherapy 5Biopsy 5Antilymphocyte Serum 5Oxaliplatin 4Nuclear Medicine Department, Hospital 4Nivolumab 4Methylprednisolone 4Ifosfamide 4Cisplatin 4palbociclib 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × pazopanib × Sarcoma × Clear all
NCT01130623 2017-07-02

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡